FREE CONSULTATION CALL
Injured? Here are your next steps

We Go The Extra Distance For Our Clients

Practice Areas

Sandy Springs and Atlanta GLP-1 Lawsuit Attorneys

Comprehensive Legal Representation for GLP-1 Claims in Atlanta and Throughout Fulton County

Thousands of patients are now coming forward with GLP-1 lawsuits after suffering unexpected health complications from popular weight loss drugs such as Ozempic and Wegovy. At Ashenden & Associates, our law firm represents weight loss patients and diabetes patients in Sandy Springs and Atlanta who have experienced severe injuries, including stomach paralysis, severe and prolonged vomiting, gastrointestinal injuries, and even vision loss.

If you or a loved one has suffered injuries from GLP-1 drugs, our legal team can guide you through the process of filing legal claims and seeking compensation. Call 770-394-8909 today or complete our online form to schedule your free consultation.

Our Legal Team Files Lawsuits for Ozempic and Other GLP-1 Weight Loss Drugs

At Ashenden & Associates, our Sandy Springs personal injury attorneys are actively pursuing lawsuits against drug manufacturers who promoted GLP-1 drugs like Ozempic, Wegovy, and Rybelsus as safe weight loss medications without adequately warning consumers of the potential risks.

Many patients prescribed Ozempic or similar GLP-1 receptor agonist drugs to treat diabetes or support weight management have reported severe and prolonged vomiting, stomach paralysis, intestinal obstruction, and other serious gastrointestinal injuries.

Lawsuits filed across the country, including multidistrict litigation in federal court, allege that pharmaceutical companies like Novo Nordisk and Eli Lilly failed to properly warn patients and healthcare providers about these dangers. Our law firm is committed to representing clients in Sandy Springs and Atlanta who have suffered injuries, lost income, and mounting medical expenses due to these dangerous drugs.

Sandy Springs and Atlanta GLP-1 Lawsuit Attorneys

Understanding Georgia GLP-1 Lawsuits

Patients across Georgia are beginning to join weight loss drug lawsuits against pharmaceutical companies over the dangerous side effects linked to GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Rybelsus.

These GLP-1 lawsuits claim that drug manufacturers failed to adequately warn consumers and healthcare providers about the heightened risk of severe gastrointestinal injuries, stomach paralysis, permanent vision loss, and other serious health complications.

GLP-1 Multidistrict Litigation Status 2025

As of 2025, hundreds of Ozempic lawsuits filed against Novo Nordisk have been consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania. The United States Judicial Panel on Multidistrict Litigation established this MDL to manage the increasing number of lawsuits that raise similar allegations.

The majority of weight loss drug lawsuits filed claim that the companies failed to warn patients about the risk of delayed gastric emptying, severe gastroparesis, intestinal blockages, and vision loss, such as non-arteritic anterior ischemic optic neuropathy (NAION). The MDL process allows plaintiffs’ lawyers to streamline discovery, share evidence such as clinical trial data and adverse event reports, and strengthen legal claims against the drug manufacturers.

Class Action Lawsuit Filed Against GLP-1 Drug Manufacturers Novo Nordisk and Eli Lilly and Company

In addition to multidistrict litigation, plaintiffs have also sought class action lawsuits against Novo Nordisk and Eli Lilly, the companies that manufacture and market semaglutide drugs, including Ozempic and Wegovy. These class actions allege that the drug makers engaged in misleading marketing campaigns, failed to provide adequate warnings, and ignored growing concerns raised in medical literature and post-marketing surveillance about serious side effects, including gastrointestinal disorders, cyclic vomiting syndrome, and sudden vision loss.

While class action lawsuits group together many plaintiffs with similar claims, injured patients in Georgia may also pursue individual lawsuits that can be transferred to the ongoing multidistrict litigation. Both types of legal action aim to hold pharmaceutical companies accountable for the harm caused and to seek financial compensation for medical expenses, lost income, and other damages.

Sandy Springs and Atlanta GLP-1 Lawsuit Lawyers

Lawsuits Filed Against Novo Nordisk

Plaintiffs across the United States have filed weight loss drug lawsuits against Novo Nordisk, alleging harm caused by several of its GLP-1 receptor agonist medications. These medications, originally developed to treat diabetes and support weight management, have been linked to severe gastrointestinal injuries, stomach paralysis, vision loss, and other serious health complications.

Patients in Sandy Springs and Atlanta who were prescribed these drugs and suffered injuries may have legal claims against Novo Nordisk for failure to adequately warn consumers and healthcare providers about the significant risks.

Ozempic

Ozempic is a semaglutide drug that was FDA-approved as a diabetes medication to help patients manage blood sugar levels. However, Ozempic quickly gained attention for its weight loss benefits, leading to widespread off-label use by weight loss patients.

Many lawsuits filed against Novo Nordisk allege that Ozempic users experienced severe and prolonged vomiting, delayed gastric emptying, bowel obstruction, and serious eye conditions such as anterior ischemic optic neuropathy. These Ozempic lawsuits claim that Novo Nordisk failed to adequately warn patients of the significant risks, despite growing concerns and evidence from clinical trials and adverse event reports.

Wegovy is marketed as a weight loss drug for chronic weight management for adults to treat obesity. While heavily promoted for its weight loss benefits, lawsuits argue that Wegovy caused serious gastrointestinal issues, severe dehydration, and prolonged vomiting requiring hospitalization.

Plaintiffs allege that Novo Nordisk’s marketing campaign misled consumers by focusing on the benefits of weight loss while downplaying the potential for severe health risks, including intestinal blockages and stomach paralysis. Patients have filed ongoing lawsuits against Novo Nordisk and Eli Lilly, claiming the companies failed to properly warn them of these dangers.

Rybelsus, another semaglutide drug made by Novo Nordisk, is an oral GLP-1 receptor agonist prescribed to treat type 2 diabetes. Rybelsus, like Ozempic and Wegovy, has caused serious health complications, including gastrointestinal injuries, acid reflux, and vision problems such as sudden blindness.

Patients and plaintiffs’ lawyers argue that Novo Nordisk failed to warn prescribing physicians and patients about the risks of delayed gastric emptying and other serious side effects. As more plaintiffs file lawsuits, Rybelsus plays an increasingly significant role in the multidistrict litigation against Novo Nordisk.

Victoza, a GLP-1 medication marketed to treat type 2 diabetes, is also included in lawsuits that allege severe injuries and dangerous side effects. Patients claim that using Victoza has caused gastrointestinal disorders, drug-induced pancreatitis, and severe health complications that required emergency care. Lawsuits allege that Novo Nordisk had a legal duty to provide adequate warnings but failed to properly inform consumers of the potential link between Victoza and severe health issues.

Saxenda, another weight loss drug manufactured by Novo Nordisk, is prescribed for patients to treat obesity and other chronic weight management needs. Lawsuits allege that Saxenda, like other GLP-1 receptor agonist drugs, has caused serious gastrointestinal injuries, severe vomiting, and increased risk of stomach paralysis. Plaintiffs claim that Novo Nordisk failed to properly warn patients and healthcare providers about these dangers, while promoting Saxenda as a safe means of weight loss.

Generic and Biosimilar Versions

In addition to the brand name Saxenda, lawsuits may also involve generic and biosimilar versions of GLP-1 receptor agonists that contain the same active ingredient. Patients who were prescribed these alternatives and suffered severe injuries such as intestinal obstruction, gastrointestinal disorders, or vision loss may also be eligible to file legal claims.

Plaintiffs have filed lawsuits against Novo Nordisk and other drug companies, alleging that all versions of these drugs carried significant risks and that the companies failed to adequately warn consumers. At Ashenden & Associates, our law firm is reviewing claims from patients in Sandy Springs and Atlanta who suffered health complications after taking Saxenda or its generic equivalents.

Lawsuits Filed Against Eli Lilly

Along with Novo Nordisk, Eli Lilly and Company faces a growing number of lawsuits involving its GLP-1 receptor agonist drugs. Patients prescribed Eli Lilly medications for diabetes treatment and weight management allege that these drugs caused severe gastrointestinal injuries, stomach paralysis, and vision loss, and that the company failed to provide adequate warnings about these risks. Lawsuits filed against Eli Lilly are being consolidated into the same multidistrict litigation alongside claims against Novo Nordisk, as many plaintiffs allege similar injuries and legal issues.

Monjauro

Mounjaro, FDA-approved in 2022 for the treatment of type 2 diabetes, is one of Eli Lilly’s most widely discussed drugs due to its reported weight loss benefits. Like other GLP-1 medications, Mounjaro has been prescribed to both diabetes patients and weight loss patients, but lawsuits claim that many suffered severe side effects, including delayed gastric emptying, bowel obstruction, cyclic vomiting syndrome, and even permanent vision loss.

Plaintiffs allege that Eli Lilly failed to adequately warn consumers and healthcare providers about these dangers, despite adverse event reports and medical literature raising serious concerns. As more plaintiffs file lawsuits, Mounjaro has become a major focus in the ongoing Ozempic litigation MDL.

Trulicity, another diabetes drug developed by Eli Lilly, is also named in lawsuits that highlight the risks of gastrointestinal injuries, abdominal pain, nausea, and drug-induced pancreatitis. Patients allege that the company marketed Trulicity as a safe option for controlling blood sugar levels but failed to warn about the increased risk of serious health issues.

Many plaintiffs claim they suffered injuries that required hospitalization, lost income, and ongoing medical treatment. These lawsuits filed against Eli Lilly argue that the company prioritized profits over patient safety by ignoring red flags and failing to provide adequate warnings about Trulicity’s potential risks.

Sandy Springs and Atlanta GLP-1 Lawsuit Attorney

Other Cases Our Sandy Springs and Atlanta GLP-1 Attorney Team Handles

At Ashenden & Associates, our GLP-1 lawsuit legal team represents clients in Sandy Springs and Atlanta who have suffered injuries not only from Novo Nordisk and Eli Lilly drugs but also from other dangerous drugs and negligent practices tied to GLP-1 receptor agonists. Beyond Ozempic and Wegovy, lawsuits are being filed against additional drug manufacturers and even compounding pharmacies that provided unsafe versions of semaglutide.

Byetta and Bydureon Lawsuit Against AstraZeneca

Byetta and Bydureon, GLP-1 receptor agonist drugs manufactured by AstraZeneca, were marketed as prescription drugs to treat type 2 diabetes and improve blood sugar control. However, lawsuits allege these drugs caused serious side effects such as pancreatitis, gastrointestinal disorders, and even thyroid tumors.

Plaintiffs allege that AstraZeneca failed to adequately warn patients and prescribing physicians about the potential risks, despite growing concerns within the medical community and clinical trial data suggesting dangers. Our Sandy Springs weight loss drug lawsuit attorneys represent clients who suffered severe injuries after taking Byetta or Bydureon and are seeking compensation for medical expenses, lost wages, and ongoing treatment needs.

In addition to lawsuits against large pharmaceutical companies, our legal team also handles claims against negligent compounding pharmacies. When brand-name drugs like Ozempic and Wegovy experienced shortages, many patients turned to compounded semaglutide formulations, which are provided by local pharmacies.

Unfortunately, some of these compounded versions were improperly prepared, mislabeled, or lacked FDA approval, creating serious health risks for patients. Lawsuits allege that certain pharmacies failed to properly warn patients of potential risks, resulting in severe gastrointestinal injuries, prolonged vomiting, and other complications. Patients harmed by compounded semaglutide may have strong legal claims against these negligent pharmacies.

Common Semaglutide Compounded Formulations

Compounded semaglutide is often marketed under names that mimic brand drugs, such as “semaglutide with B12” or “semaglutide sodium.” These compounded formulations are not FDA-approved, and many lack safety testing and quality control. Patients who used these versions have reported severe gastroparesis, intestinal blockages, and other gastrointestinal injuries. Because compounded semaglutide may differ in purity and strength compared to FDA-approved medications, the risks can be even greater.

Our Sandy Springs and Atlanta weight loss drug lawsuit attorneys are reviewing claims involving compounded semaglutide products and helping patients pursue financial compensation from negligent pharmacies that failed to protect consumer safety.

Some lawsuits against healthcare providers involve medical malpractice claims tied to off-label use of GLP-1 receptor agonists. While these drugs were FDA-approved for diabetes treatment and, in limited cases, for weight loss management, many doctors prescribed them more broadly without adequately warning patients of the potential risks.

Patients in Sandy Springs and Atlanta who suffered severe gastrointestinal injuries, stomach paralysis, or vision loss may have claims not only against drug manufacturers but also against prescribing physicians who failed to follow safe prescribing practices or warn patients about significant risks.

Prescribing Ozempic and Other GLP-1 Drugs Not FDA Approved For Weight Loss to Non-Diabetic Patients

A growing number of lawsuits allege that prescribing Ozempic and other GLP-1 drugs to non-diabetic patients for weight loss created preventable harm. The FDA approved Ozempic as a diabetes medication to control blood sugar levels, but it never approved the drug for weight loss.

Lawsuits allege that some doctors encouraged off-label use of these medications for weight loss patients without providing adequate warnings about possible side effects like delayed gastric emptying, severe gastroparesis, and sudden vision loss. Patients who suffered injuries from off-label use may have legal options against both drug manufacturers and negligent prescribers.

Off-Label Prescriptions for Pediatric Patients

Lawsuits also focus on off-label prescriptions for pediatric patients, where children and teens were prescribed GLP-1 drugs such as Ozempic and Wegovy without FDA approval for this age group. Parents allege that prescribing physicians and drug companies failed to adequately warn about the increased risk of gastrointestinal disorders, prolonged vomiting, and other serious health complications in younger patients. Because pediatric patients were never included in most clinical trials for these drugs, plaintiffs argue that prescribing them off-label created unacceptable dangers.

Another emerging legal issue involves claims for “research-grade” peptides sold as alternatives to FDA-approved GLP-1 medications. These unregulated products, sometimes marketed as semaglutide peptides, are not approved for human use and lack safety testing.

Lawsuits allege that patients who took these peptides suffered severe health issues, including gastrointestinal injuries and other complications. Plaintiffs argue that distributors and pharmacies selling research-grade peptides acted irresponsibly by promoting unsafe alternatives, thereby placing patients at risk.

With the rise of telehealth and online pharmacies, many patients obtained GLP-1 weight loss medications through online distributors that failed to provide adequate warnings or proper medical oversight.

Consumers allege in lawsuits that these companies sold compounded or mislabeled semaglutide products without providing informed consent about the dangers. Some patients report suffering severe dehydration, intestinal obstruction, or permanent vision loss after taking these online-purchased medications.

Legal claims argue that these distributors put profits above patient safety by skipping required safeguards, leaving patients in Sandy Springs and Atlanta with serious injuries and growing medical expenses.

Sandy Springs and Atlanta GLP-1 Lawsuit Lawyer

GLP-1 Medications Linked to Serious Health Complications

While GLP-1 receptor agonist drugs such as Ozempic, Wegovy, Rybelsus, and Mounjaro have been widely promoted for their weight loss benefits and ability to treat type 2 diabetes, many patients have reported severe health issues after taking these medications.

Lawsuits argue that drug manufacturers failed to adequately warn consumers and healthcare providers about the significant risks tied to these drugs. Patients in Sandy Springs and Atlanta have joined lawsuits after experiencing long-term injuries that required hospitalization, ongoing treatment, and significant medical expenses. Below are some of the most common health complications associated with GLP-1 lawsuits.

Gastroparesis / Stomach Paralysis

One of the most alarming complications linked to GLP-1 medications is gastroparesis, also known as stomach paralysis. This condition occurs when the stomach muscles slow down and are unable to properly move food through the digestive system, resulting in delayed gastric emptying. Patients report symptoms such as severe and prolonged vomiting, nausea, abdominal pain, and malnutrition. Many lawsuits allege that pharmaceutical companies knew of the risk of severe gastroparesis but failed to adequately warn consumers, leaving patients with debilitating, ongoing symptoms.

Another growing concern involves vision loss linked to non-arteritic anterior ischemic optic neuropathy (NAION). This serious eye condition reduces blood flow to the optic nerve and can cause sudden blindness or permanent vision loss.

Plaintiffs allege that Novo Nordisk and Eli Lilly failed to provide adequate warnings about this risk, even as reports of anterior ischemic optic neuropathy and other vision problems grew in post-marketing surveillance. Lawsuits filed against these companies include claims for permanent vision damage suffered by Ozempic users and patients taking similar GLP-1 drugs.

GLP-1 receptor agonist drugs have also been linked to drug-induced pancreatitis, a painful and sometimes life-threatening inflammation of the pancreas. Patients have reported severe abdominal pain, nausea, and vomiting that required emergency care.

Lawsuits allege that the drug manufacturers failed to warn about the heightened risk of pancreatitis, despite evidence from clinical trial data and adverse event reports. Some plaintiffs’ lawyers argue that this failure to warn represents a serious breach of the drug makers’ legal duty to protect consumers.

Many patients have also suffered intestinal obstruction, where blockages in the small or large intestine disrupt normal digestion and require hospitalization or surgery. This condition has been linked to delayed gastric emptying and other gastrointestinal issues caused by GLP-1 medications. Lawsuits filed allege that drug companies ignored significant evidence of these risks and continued to market these drugs as safe weight loss medications.

GLP-1 weight loss medications have also been associated with gallbladder disease and gallstones, leading to severe pain, digestive system issues, and, in some cases, gallbladder removal surgery. Plaintiffs allege that pharmaceutical companies failed to provide adequate warnings about these risks on product labels and in marketing materials.

Reports have also linked GLP-1 receptor agonist drugs to kidney disease and acute kidney injury, sometimes requiring dialysis or long-term treatment. Lawsuits allege that drug manufacturers failed to warn prescribing physicians and patients of the risk of kidney damage, leaving patients vulnerable to severe health issues.

Some lawsuits allege that GLP-1 medications increase the risk of thyroid tumors and medullary thyroid carcinoma, a rare but aggressive form of thyroid cancer. Clinical trial data raised concerns about thyroid tumors in laboratory studies, yet drug makers continued to market these drugs without adequately warning consumers. Patients diagnosed with thyroid cancer after taking GLP-1 weight loss medications may have strong legal claims for compensation.

Another serious side effect linked to GLP-1 drugs is worsening diabetic retinopathy, an eye disease caused by damage to blood vessels in the retina. Lawsuits argue that drug manufacturers failed to properly warn diabetes patients that these medications may increase the risk of vision problems.

In addition to physical complications, some patients have reported psychiatric side effects such as depression, anxiety, and suicidal thoughts after taking GLP-1 weight loss medications. Lawsuits allege that manufacturers failed to warn patients and healthcare providers about these potential risks, despite reports suggesting a possible link. Plaintiffs claim that these adverse effects have caused significant emotional distress, ongoing symptoms, and, in some cases, required emergency care.

Sandy Springs and Atlanta GLP-1 Lawsuits

How to Join an Ozempic Class Action Lawsuit or Other GLP-1 Class Action Lawsuit in Atlanta or Sandy Springs

Patients in Sandy Springs and Atlanta who suffered severe injuries after taking GLP-1 drugs such as Ozempic, Wegovy, or Rybelsus may have the option to join an Ozempic class action lawsuit or other GLP-1 class action lawsuits.

These lawsuits claim that drug manufacturers like Novo Nordisk and Eli Lilly failed to adequately warn patients about the significant risks, including stomach paralysis, intestinal obstruction, vision loss, and other serious health complications. If you or a loved one experienced severe side effects from GLP-1 drugs, understanding the eligibility process and your legal options can help you decide the best path forward.

Weight Loss Drug Class Action Eligibility Criteria

To join a weight loss drug class action lawsuit, patients must prove that they used or were prescribed a GLP-1 receptor agonist such as Ozempic, Wegovy, or Rybelsus and then suffered injuries potentially linked to the drug.

Common claims include gastrointestinal injuries, delayed gastric emptying, gallbladder disease, pancreatitis, or permanent vision loss. Plaintiffs must also demonstrate that the drug manufacturer failed to warn about these risks. Our law firm reviews medical records, prescription histories, and healthcare provider notes to determine if patients in Sandy Springs and Atlanta meet the eligibility requirements to participate in a class action.

Class Action vs. Individual Personal Injury Actions

When pursuing legal claims against drug manufacturers, patients may choose between joining a class action lawsuit or filing an individual personal injury action. A class action lawsuit allows many plaintiffs with similar claims to pursue legal action together, often focusing on issues like false advertising, failure to warn, and misleading statements by pharmaceutical companies.

Individual personal injury actions, however, may be a better option for patients who have suffered severe or unique injuries, as these cases can seek compensation tailored to their medical expenses, lost income, and long-term care needs. Our attorneys help patients in Sandy Springs and Atlanta understand whether joining a class action or pursuing an individual case will provide the strongest opportunity for financial compensation.

When to File a Sandy Springs or Atlanta GLP-1 Lawsuit Individually?

While many patients harmed by GLP-1 drugs such as Ozempic, Wegovy, or Mounjaro may join a class action lawsuit or multidistrict litigation, others may benefit more from filing an individual lawsuit. Patients in Sandy Springs and Atlanta who suffered unique or especially severe injuries may be able to pursue compensation through a personal injury action tailored to their specific losses. Individual cases may also focus on product liability or even medical malpractice if prescribing physicians acted negligently.

Diabetes Patients or Weight Loss Patients With Unique Injuries

Some diabetes patients and weight loss patients experienced injuries so severe that their circumstances differ from the broader group of plaintiffs. Examples include permanent vision loss, severe gastroparesis requiring feeding tubes, or kidney failure requiring dialysis.

In these cases, an individual GLP-1 lawsuit may provide the best chance of recovering compensation for extensive medical expenses, lost income, and long-term treatment needs. These patients may also present unique claims that require focused attention rather than being grouped into a broader class action.

Many individual lawsuits focus on product liability claims, alleging that drug manufacturers failed to adequately warn consumers and healthcare providers of the risks tied to GLP-1 receptor agonists. Plaintiffs argue that companies like Novo Nordisk and Eli Lilly ignored clinical trial data, post-marketing surveillance, and adverse event reports that pointed to dangers such as stomach paralysis, intestinal obstruction, and permanent vision damage. In some cases, plaintiffs also allege defects in the drug’s design or labeling. Filing an individual lawsuit allows patients to present evidence specific to their injuries and hold pharmaceutical companies accountable for the harm caused.

Individual lawsuits may also include medical malpractice claims against prescribing physicians or healthcare providers. Some doctors prescribed Ozempic or other GLP-1 drugs off-label for weight loss to non-diabetic patients or even pediatric patients, without FDA approval and without giving adequate warnings about the risks. Others failed to properly monitor patients for signs of severe gastrointestinal injuries, pancreatitis, or vision loss.

In these cases, patients may have claims for negligence, lack of informed consent, or inadequate monitoring. Filing an individual lawsuit allows injured patients in Sandy Springs and Atlanta to hold not just drug manufacturers but also negligent healthcare providers accountable.

Our Sandy Springs and Atlanta GLP-1 Lawsuit Attorneys Seek Maximum Compensation for Clients Throughout Georgia

At Ashenden & Associates, our GLP-1 lawsuit attorneys fight for patients across Sandy Springs, Atlanta, and throughout Georgia who have suffered severe injuries after taking GLP-1 receptor agonist drugs such as Ozempic, Wegovy, Rybelsus, and Mounjaro.

We understand the financial and emotional toll that serious health complications, like stomach paralysis, intestinal obstruction, pancreatitis, or permanent vision loss, can create for patients and their families. Our legal team pursues maximum compensation in every case, including damages for medical expenses, lost income, ongoing treatment, pain and suffering, and long-term care needs.

Whether your claim involves multidistrict litigation, a class action, or an individual personal injury action, our law firm is committed to holding drug manufacturers, negligent pharmacies, and healthcare providers accountable for the harm caused by dangerous drugs.

Why Choose Our Sandy Springs and Atlanta GLP-1 Law Firm

At Ashenden & Associates, our GLP-1 lawsuit attorneys understand the serious health complications patients face from drugs like Ozempic, Wegovy, Rybelsus, and Mounjaro. We represent both diabetes patients and weight loss patients in Sandy Springs, Atlanta, and throughout Georgia who trusted these medications but instead experienced severe gastrointestinal injuries, vision loss, kidney disease, or other long-term complications.

Our legal team works directly with clients to review medical records, evaluate potential claims, and build strong cases against drug manufacturers, pharmacies, or negligent healthcare providers. We are committed to pursuing the maximum financial recovery for your medical expenses, lost wages, and pain caused by these dangerous drugs.

Steps for Legal Action if You’ve Been Harmed By GLP-1 Medications in Georgia

If you’ve suffered injuries after taking GLP-1 medications such as Ozempic, Wegovy, Rybelsus, or Mounjaro, there are important steps you can take to protect your rights. First, seek medical care immediately and keep detailed medical records of your diagnosis, treatment, and any ongoing symptoms such as severe vomiting, abdominal pain, or vision problems. Next, gather documentation of your prescriptions, including the prescribing physician and pharmacy records, as this information will support your legal claims.

Then, contact our Sandy Springs and Atlanta GLP-1 lawsuit attorneys at Ashenden & Associates to review your case. Our legal team will evaluate whether your injuries may be linked to GLP-1 receptor agonist drugs, explain your legal options, and guide you through filing an individual lawsuit, joining a class action, or being included in multidistrict litigation.

Taking action quickly gives you the strongest chance to seek financial compensation for medical expenses, lost income, and other damages caused by dangerous drugs. Call 770-394-8909 today for a free consultation.

Atlanta Area Medical Resources for GLP-1 Complications

Sandy Springs and Atlanta GLP-1 Lawsuit Law Firm

Contact A Sandy Springs and Atlanta GLP-1 Lawyer For a Free Consultation

If you or someone you love has suffered severe injuries after taking Ozempic, Wegovy, Rybelsus, Mounjaro, or other GLP-1 medications, now is the time to take legal action. Dangerous drugs can leave patients with lifelong complications, overwhelming medical expenses, and lost income, but you don’t have to face these challenges alone.

At Ashenden & Associates, our Sandy Springs and Atlanta GLP-1 lawsuit attorneys are committed to holding drug manufacturers and negligent healthcare providers accountable while fighting for the maximum compensation you deserve. Contact us today at 770-394-8909 or through our online contact page to schedule your free consultation and start protecting your rights.